Skip to main content
RAMM Pharma Corp. logo

RAMM Pharma Corp. — Investor Relations & Filings

Ticker · RAMM CSE Manufacturing
Open in API
Filings indexed 134 across all filing types
Latest filing 2025-06-26 Proxy Solicitation & In…
Country CA Canada
Listing CSE RAMM

About RAMM Pharma Corp.

https://www.wearerammpharma.com/

RAMM Pharma Corp. is a pharmaceutical and medical product company specializing in cannabinoid pharmacology and product formulation. The company develops and commercializes plant-derived cannabinoid pharmaceuticals, cosmetics, and pet care products. Key operations include Medic Plast, which produces medically registered prescription CBD solutions (Epifractán and Xalex 10) approved by the Ministry of Public Health of Uruguay. RAMM also addresses the pet market through NettaLife (NettaVet CBD drops and NettaPet food) and the European cosmetic and nutraceutical sectors via Canapar, which operates a high-tech cannabis extraction facility in Sicily. The company utilizes cultivation facilities in Uruguay and focuses on expanding distribution agreements across Latin America.

Recent filings

Filing Released Lang Actions
Notice of the meeting and record date - English.pdf
Proxy Solicitation & Information Statement Classification · 75% confidence The document is a formal “Notice of Meeting and Record Date” for the issuer’s upcoming Annual General Meeting, filed via SEDAR+. It is part of the proxy solicitation process, informing shareholders of the meeting details and voting record dates. This aligns with the Proxy Solicitation & Information Statement category rather than an actual AGM presentation or full annual report.
2025-06-26 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 90% confidence The document is a Form 52-109FV2 Certification of Interim Filings – a statutory certificate by the CFO under Canadian NI 52-109 for a venture issuer’s interim financial report and MD&A. It is not the interim report itself but a mandatory regulatory compliance filing. It does not present the financials or MD&A content, nor announce dividend, management change, or fundraising. Therefore it falls under the fallback category for miscellaneous regulatory filings.
2025-04-01 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 82% confidence The document is a certification (Form 52-109FV2) by the CEO regarding review and fair presentation of interim financial report and interim MD&A under NI 52-109. It is not the interim report itself but a regulatory attestation accompanying those filings. It does not contain financial results or analysis, nor is it a notice of publication, management discussion & analysis, or audit report. It is best classified as a general regulatory filing under RNS.
2025-04-01 English
Interim MD&A - English.pdf
Management Reports Classification · 100% confidence The document is a 'Management's Discussion and Analysis' (MD&A) report for RAMM Pharma Corp. for the three-month period ended January 31, 2025. It provides a detailed narrative explanation of the company's business operations, regulatory environment, and strategic outlook, which is the standard content for an MDA filing. While it references interim financial statements, the document itself is the management commentary component of the quarterly reporting package. Q1 2025
2025-04-01 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Condensed Interim Consolidated Financial Statements' for RAMM Pharma Corp. for the three months ended January 31, 2025. It includes a management responsibility statement, a notice of no auditor review, a table of contents, and full financial statements (Statement of Financial Position, Statement of Loss and Comprehensive Loss, Statement of Changes in Equity, and Statement of Cash Flows), along with detailed notes. This meets the definition of an Interim/Quarterly Report (IR) as it contains substantive financial data and analysis for a period shorter than a full fiscal year. Q1 2025
2025-04-01 English
52-109FV1 - Certification of annual filings - CFO (E).pdf
Regulatory Filings Classification · 84% confidence The document is a regulatory certificate (Form 52-109FV1) by the CFO certifying the annual filings under Canadian NI 52-109 for a venture issuer. It is not the annual report itself (10-K or IR), nor an earnings release, management discussion, or investor presentation. It’s a mandatory regulatory certificate filing and therefore best fits the fallback category “Regulatory Filings” (RNS).
2025-03-04 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.